Literature DB >> 16949182

Intranasal administration of chlamydial outer protein N (CopN) induces protection against pulmonary Chlamydia pneumoniae infection in a mouse model.

A Tammiruusu1, T Penttilä, R Lahesmaa, M Sarvas, M Puolakkainen, J M Vuola.   

Abstract

Chlamydia pneumoniae is an intracellular pathogen that grows inside a vacuole, referred to as an inclusion. C. pneumoniae possess a type III secretion system (TTSS), which allows them to secrete effector molecules into the inclusion membrane and to the host cell cytosol. Proteins such as chlamydial outer protein N (CopN) that associate with the inclusion membrane are potential targets for the host's MHC-dependent antigen presentation, thereby representing ideal antigen candidates for T cell-based vaccination. The results of this study showed that intranasal immunization of BALB/c mice with heat-aggregated CopN protein and an Escherichia coli heat-labile toxin (LT) induced a strong immune response, detected as antigen-specific antibody production, lymphocyte proliferation and IFN-gamma production. Furthermore, the immunization induced statistically significant protection against intranasal C. pneumoniae challenge, the level of which correlated with the magnitude of CopN-specific lymphocyte proliferation. Both heat-aggregation of the antigen and the presence of LT adjuvant were required for maximal protective effect.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16949182     DOI: 10.1016/j.vaccine.2006.07.043

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Protective immunity against mouse upper genital tract pathology correlates with high IFNγ but low IL-17 T cell and anti-secretion protein antibody responses induced by replicating chlamydial organisms in the airway.

Authors:  Chunxue Lu; Hao Zeng; Zhihong Li; Lei Lei; I-Tien Yeh; Yimou Wu; Guangming Zhong
Journal:  Vaccine       Date:  2011-11-10       Impact factor: 3.641

Review 2.  Type III secretion systems and disease.

Authors:  Bryan Coburn; Inna Sekirov; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

3.  Simultaneous Intramuscular And Intranasal Administration Of Chitosan Nanoparticles-Adjuvanted Chlamydia Vaccine Elicits Elevated Protective Responses In The Lung.

Authors:  Yumeng Li; Chuan Wang; Zhenjie Sun; Jian Xiao; Xiaoliang Yan; Yuqing Chen; Jian Yu; Yimou Wu
Journal:  Int J Nanomedicine       Date:  2019-10-08

4.  Novel Chlamydia pneumoniae vaccine candidates confirmed by Th1-enhanced genetic immunization.

Authors:  Yihang Li; Sudhir K Ahluwalia; Alexandre Borovkov; Andrey Loskutov; Chengming Wang; Dongya Gao; Anil Poudel; Kathryn F Sykes; Bernhard Kaltenboeck
Journal:  Vaccine       Date:  2009-12-02       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.